Data Integrity and ALCOA Principles in Pharma Manufacturing

As pharmaceutical manufacturing becomes more digital, data integrity and ALCOA principles face new challenges.

Digital twins, continuous manufacturing, process analytical technology (PAT), and human factors can create new risks for traceability, contemporaneous records, and auditability. 

Image

Digital Manufacturing Creates A New Data Integrity Problem

Digital twins can create a live virtual representation of a physical manufacturing process. Combined with IoT sensors, PAT, machine learning, and process models, they can support real-time monitoring, predictive quality control, and process optimisation.

This creates a more complicated data environment.

The data integrity and ALCOA challenge is no longer limited to laboratory notebooks, batch records, or conventional electronic systems as data can now move continuously between physical equipment, sensors, software, cloud platforms, analytical models, and virtual representations of manufacturing processes.

A very recent Journal of Pharmaceutical Innovation review examined data integrity failures and risks associated with digital twins and continuous manufacturing. It covered literature and regulatory sources from 2020 to 2026 and identified 248 studies or incidents meeting its inclusion criteria. 

The authors used ALCOA++ alongside human factors analysis and simulation risks to build a framework for understanding where digital manufacturing can weaken data integrity.

The review’s framework essentially assumes, and proves, that data integrity is ensured with nine principles of ALCOA++: Attributable (who), Legible (readable), Contemporaneous (timely), Original (source), Accurate (without error), and Complete (whole), Consistent (logical), Enduring (permanent), Available (accessible), and Traceable (auditable).

ALCOA Must Extend to Digital Twins

ALCOA remains a fundamental way to assess whether regulated data can be trusted.

The principles require data to be:

• Attributable: linked to the person or system responsible.
• Legible: readable and understandable.
• Contemporaneous: recorded when the activity occurs.
• Original: preserved in its original form or as a verified true copy.
• Accurate: free from inappropriate error.

ALCOA++ extends this thinking to include complete, consistent, enduring, available, and traceable data.

The U.S. Food and Drug Administration (FDA) describes data integrity in similar terms, defining it around the completeness, consistency, and accuracy of data throughout its lifecycle. 

The problem is that digital twins introduce data that may not behave like conventional records.

Models can change, and sensor feeds can lag with data synchronising incorrectly. Additionally, AI systems can generate outputs that are difficult to reconstruct.

On the human-side, operators can override automated decisions and there is a major area of risk in these interactions between technology and people. 

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Where Digital Twins Can Break Data Integrity

Data integrity risks can be grouped as technical vulnerabilities, human factors, and regulatory gaps. 

Model drift, synchronisation problems, high-volume data flows, operator overrides, and incomplete audit trails are all important concerns. 

Concerning timing, 65% of identified failures involve non-contemporaneous data, meaning records are not reliably captured at the time the relevant activity occurred and where traceability problems involving virtual and physical data flows can occur.

This matters in continuous manufacturing because production does not always create the clear boundaries found in traditional batch processes.

A continuous stream of sensor readings, model outputs, operator interventions, and automated decisions can make it harder to reconstruct exactly what happened, when it happened, and why.

That creates a direct challenge for inspection readiness.

Human Factors Are Still the Central Challenge for Data Integrity and ALCOA

Digital transformation does not remove human error. Instead it changes how that error can occur.

Operators may need to interpret model outputs while responding to production events. They may override recommendations, correct data, or intervene when a physical process diverges from its digital representation.

In this regard, cognitive overload, training gaps, skill-based errors, and decision errors are important contributors to data integrity risks. 

This is critical because a compliant digital system is not enough if employees do not understand how its audit trails, models, data flows, and exception processes work.

The UK’s MHRA similarly states that data governance should address ownership and accountability across the data lifecycle, while organisations should create an environment that encourages the reporting of errors and undesirable results. 

Data integrity is therefore both a technology issue and an organisational one.

Image

Building Trust Into Digital Pharma Manufacturing

To address data integrity and ALCOA challenges, the Springer review proposes a Digital Twin Compliance Framework that combines human-centred design, risk assessment, hybrid audit trails, and anomaly detection.

In reported simulations, this approach reduced simulated failure rates by almost 70%.

This shows the importance of pharma embedding data integrity and ALCOA principles into system design, validation, governance, training, and change management.

That becomes more important as manufacturers adopt continuous production, advanced PAT, AI-supported decisions, and digital twins.

Pharmatica’s analysis of continuous manufacturing examines how manufacturing models are changing. Our analysis of cold chain optimisation similarly shows how increasingly connected operations depend on reliable data and decision-making.

On the regulatory front, FDA guidance states that data integrity must be maintained throughout the current GMP data lifecycle, including creation, modification, processing, maintenance, retrieval, transmission, and archival.

Data Integrity Is the Most Important Manufacturing Capability

For data integrity and ALCOA principles, it’s important to understand that the future pharma manufacturing environment will generate more data, not less.

Digital twins could support continuous process verification, real-time release testing, technology transfer, and more responsive quality control. 

These systems can become an integral part of a modern Quality-by-Design environment if they are designed and governed appropriately. 

That requires a shift in mindset.

The objective is not simply to digitise manufacturing, but to make every important digital decision explainable, attributable, traceable, and inspection-ready.

ALCOA is therefore more than a documentation principle, and is a design requirement for a connected manufacturing environment where data integrity is ensured.

At Pharmatica, we examine the systems, strategies, and technologies shaping pharmaceutical Technical Operations. Our Insights connect manufacturing innovation, data, quality, and regulation to the decisions that determine whether new technologies deliver measurable operational value.

Pharmatica: Insight. Connection. Impact.

Image